6GY2

Crystal structure of human Plk1-PBD in complex with WSSSLATPPTLSSpTVLI phosphopeptide from BRCA2

• PDB DOI:  https://doi.org/10.2210/pdb6GY2/pdb

• Classification: CELL CYCLE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2018-06-28 Released: 2019-07-10 
• Deposition Author(s): Miron, S., Ropars, V., Zinn-Justin, S.
• Funding Organization(s): National Institutes of Health/National Cancer Institute (NIH/NCI)

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 3.11 Å
• R-Value Free: 0.215 
• R-Value Work: 0.187 
• R-Value Observed: 0.189 

Literature

Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1.

Ehlen, A., Martin, C., Miron, S., Julien, M., Theillet, F.X., Ropars, V., Sessa, G., Beaurepere, R., Boucherit, V., Duchambon, P., El Marjou, A., Zinn-Justin, S., Carreira, A.

(2020) Nat Commun 11: 1819-1819

• PubMed: 32286328 
• DOI: https://doi.org/10.1038/s41467-020-15689-9
• Primary Citation of Related Structures:  
  6GY2


• PubMed Abstract: 
  

The BRCA2 tumor suppressor protein is involved in the maintenance of genome integrity through its role in homologous recombination. In mitosis, BRCA2 is phosphorylated by Polo-like kinase 1 (PLK1). Here we describe how this phosphorylation contributes to the control of mitosis. We identify a conserved phosphorylation site at T207 of BRCA2 that constitutes a bona fide docking site for PLK1 and is phosphorylated in mitotic cells. We show that BRCA2 bound to PLK1 forms a complex with the phosphatase PP2A and phosphorylated-BUBR1. Reducing BRCA2 binding to PLK1, as observed in BRCA2 breast cancer variants S206C and T207A, alters the tetrameric complex resulting in unstable kinetochore-microtubule interactions, misaligned chromosomes, faulty chromosome segregation and aneuploidy. We thus reveal a role of BRCA2 in the alignment of chromosomes, distinct from its DNA repair function, with important consequences on chromosome stability. These findings may explain in part the aneuploidy observed in BRCA2-mutated tumors.

---

Organizational Affiliation: 

Paris Sud University, Paris-Saclay University CNRS, UMR3348, F-91405, Orsay, France. [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B1 

Biological assembly 1 generated by PISA (software)

Biological Assembly Evidence: isothermal titration calorimetry

Biological Assembly 2  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B1 

Biological assembly 2 generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 60.16 kDa 
• Atom Count: 3,842 
• Modelled Residue Count: 472 
• Deposited Residue Count: 524 
• Unique protein chains: 2

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Serine/threonine-protein kinase PLK1	A, B	245	Homo sapiens	Mutation(s): 0  Gene Names: PLK1, PLK EC: 2.7.11.21
UniProt & NIH Common Fund Data Resources
Find proteins for P53350 (Homo sapiens) Explore P53350  Go to UniProtKB:  P53350
PHAROS:  P53350

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Phosphopeptide of BRCA2	C, D	17	Homo sapiens	Mutation(s): 0  Gene Names: BRCA2, FACD, FANCD1
UniProt & NIH Common Fund Data Resources
Find proteins for P51587 (Homo sapiens) Explore P51587  Go to UniProtKB:  P51587
PHAROS:  P51587

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
GOL	E [auth A]	GLYCEROL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
TPO	C, D	L-PEPTIDE LINKING	C4 H10 N O6 P		THR

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 3.11 Å
• R-Value Free: 0.215 
• R-Value Work: 0.187 
• R-Value Observed: 0.189 
• Space Group: P 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 50	α = 80.79
b = 56.04	β = 79.23
c = 61.03	γ = 65.05

Software Package:

Software Name	Purpose
BUSTER	refinement
XDS	data reduction
XSCALE	data scaling
PDB_EXTRACT	data extraction
PHASER	phasing

Structure Validation

Entry History & Funding Information

Deposition Data

• Released Date: 2019-07-10 
Deposition Author(s): Miron, S., Ropars, V., Zinn-Justin, S.

---

Funding Organization	Location	Grant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)	France	INCa-DGOS_8706

Revision History  

• Version 1.0: 2019-07-10
  Type: Initial release
  
• Version 1.1: 2020-04-22
  Changes: Database references
• Version 1.2: 2022-03-30
  Changes: Advisory, Author supporting evidence, Database references